genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2013
Bipolar disorder
News
GEN Reports on Downfall of a Once Biotech King
Insights
Empire Crumbles for a Once Biotech King
News
Schizophrenia Drug Fails in Phase III
News
AstraZeneca Takes FDA to Court Over Generic Antipsychotic Labeling
News
Gedeon Richter, Forest Drug Cariprazine Succeeds in Third Phase III Bipoar Disorder Study
News
Forest and Gedeon Richter Report Positive Phase III Data for Antipsychotic
Industry News
Biotie to Acquire CNS Therapeutics Firm Synosia in €93.6M All-Shares Deal
News
NIH to Dole Out More Than $161M Over Five Years to Bolster Pharmacogenomic Research
News
EU Sanctions Merck & Co.’s Sublingual Bipolar Disorder Drug Sycrest
News
Cypress Pays Alexza $5M to Use Technology with Smoking Cessation Therapy
1
...
3
4
5
...
7
Page 4 of 7
Scroll Up
Scroll Up
